XML 87 R62.htm IDEA: XBRL DOCUMENT v3.24.0.1
Commitments and Contingencies (Additional Information) (Details) - USD ($)
$ in Thousands
1 Months Ended 12 Months Ended
Feb. 28, 2013
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Apr. 30, 2023
Commitments and Contingencies [Line Items]          
Finance lease liabilities   $ 0      
Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]   Derivative Liability, Noncurrent      
Lease Expense   $ 1,100 $ 500 $ 600  
Additional ROU assets   2,943 1,131   $ 2,500
Corresponding lease liabilities   2,237 665   $ 2,500
GLOPERBA [Member]          
Commitments and Contingencies [Line Items]          
Due From Related Party   500      
Former Employee [Member]          
Commitments and Contingencies [Line Items]          
Agreement settlement payment   3,500      
Former Employee One[Member]          
Commitments and Contingencies [Line Items]          
Agreement settlement payment   $ 2,500      
Epoladerm [Member]          
Commitments and Contingencies [Line Items]          
Percentage on net sale   6.00%      
Probudur [Member]          
Commitments and Contingencies [Line Items]          
Percentage on net sale   6.00%      
Envelta [Member]          
Commitments and Contingencies [Line Items]          
Percentage on net sale   6.00%      
Product Development Agreement [Member] | Developers [Member]          
Commitments and Contingencies [Line Items]          
Royalty expenses   $ 8,500 4,500    
Accrued royalty payables   2,400 2,200    
Agreement maturity date Oct. 02, 2028        
Agreement maturity renewal description The Product Development Agreement will renew automatically for subsequent successive one-year renewal periods unless Scilex Pharma or the Developers terminate it upon 6-month written notice.        
Product Development Agreement [Member] | Developers [Member] | Minimum [Member]          
Commitments and Contingencies [Line Items]          
Royalty payment percentage related to future years 25.00%        
Product Development Agreement [Member] | Developers [Member] | Maximum [Member]          
Commitments and Contingencies [Line Items]          
Royalty payment percentage related to future years 35.00%        
Product Development Agreement [Member] | Scilex Pharma [Member]          
Commitments and Contingencies [Line Items]          
Royalty expenses   $ 8,300 $ 2,300    
Non-cancelable Lease Agreements [Member] | Minimum [Member] | Research and Development Facilities [Member]          
Commitments and Contingencies [Line Items]          
Operating lease, remaining lease term   8 months 12 days      
Operating lease, lease term   3 years      
Non-cancelable Lease Agreements [Member] | Maximum [Member] | Research and Development Facilities [Member]          
Commitments and Contingencies [Line Items]          
Operating lease, remaining lease term   3 years 9 months 18 days      
Operating lease, lease term   5 years